argenx SE logo
argenx SE ARGX
$ 697.05 2.89%

Annual report 2024
added 03-14-2026

report update icon

argenx SE Market Cap 2011-2026 | ARGX

As of March 26, 2026 argenx SE has a market cap of $ 25 B


Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]

Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.

This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.

Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.

Annual Market Cap argenx SE

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
- - - 13.8 B 11.3 B 5.57 B 3.82 B 1.91 B - - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
13.8 B 1.91 B 7.27 B

References

  1. Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.

Market Cap of other stocks in the Biotechnology industry

Issuer Market Cap Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
315 M - 2.43 % $ 254 M germanyGermany
ARCA biopharma ARCA biopharma
ABIO
484 M - 1052.0 % $ 415 M usaUSA
Processa Pharmaceuticals Processa Pharmaceuticals
PCSA
4.14 M $ 2.3 -1.29 % $ 3.01 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
41.4 M - 5.93 % $ 314 M canadaCanada
Albireo Pharma Albireo Pharma
ALBO
538 M - -0.23 % $ 916 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
38.2 M - 10.36 % $ 9.8 M usaUSA
I-Mab I-Mab
IMAB
127 M - - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
33.6 B - - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
168 B - 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
549 M - -13.47 % $ 169 M franceFrance
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
7.37 B $ 220.9 2.49 % $ 5 B danmarkDanmark
Aptinyx Aptinyx
APTX
9.48 M - -39.0 % $ 4.57 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
79 M - -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
28.9 M - -1.52 % $ 24.7 M usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
1.25 B $ 19.57 1.77 % $ 915 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
32.8 M - - $ 26.5 M usaUSA
Phathom Pharmaceuticals Phathom Pharmaceuticals
PHAT
986 M $ 10.47 4.08 % $ 763 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
7.72 M - - $ 7.46 M israelIsrael
AgeX Therapeutics AgeX Therapeutics
AGE
14.1 K - -10.17 % $ 12.2 K usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
16.7 M - -24.86 % $ 820 K usaUSA
Atreca Atreca
BCEL
49 M - -11.76 % $ 5.79 M usaUSA
Acasti Pharma Acasti Pharma
ACST
40.7 M - 4.01 % $ 150 M canadaCanada
BeiGene, Ltd. BeiGene, Ltd.
BGNE
253 B - 0.49 % $ 251 B cayman-islandsCayman-islands
bluebird bio bluebird bio
BLUE
67 M - - $ 546 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
2.83 B - - - russiaRussia
Cara Therapeutics Cara Therapeutics
CARA
54.1 M - -3.03 % $ 260 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
76.4 M - - $ 86.2 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
12.1 M - 2.71 % $ 14 M usaUSA
Advaxis Advaxis
ADXS
1.87 M - -9.65 % $ 45.9 M usaUSA
Pliant Therapeutics Pliant Therapeutics
PLRX
81.6 M $ 1.31 2.34 % $ 80.4 M usaUSA
PMV Pharmaceuticals PMV Pharmaceuticals
PMVP
85.6 M $ 1.37 -1.44 % $ 72 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
544 K - -52.27 % $ 4.45 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
424 M $ 1.33 0.76 % $ 339 M britainBritain
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
127 M $ 8.31 1.59 % $ 111 M usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
4.39 B $ 47.09 1.42 % $ 4.23 B schweizSchweiz
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCC
5.58 M - -5.98 % $ 34.1 M usaUSA
ChemoCentryx ChemoCentryx
CCXI
1.82 M - - $ 3.74 B usaUSA
Prelude Therapeutics Incorporated Prelude Therapeutics Incorporated
PRLD
277 M $ 3.26 4.49 % $ 251 M usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
1.73 B - - $ 2.02 B usaUSA
ProQR Therapeutics N.V. ProQR Therapeutics N.V.
PRQR
68.7 M $ 1.58 6.04 % $ 99.5 M niderlandNiderland
BioDelivery Sciences International BioDelivery Sciences International
BDSI
308 M - -4.8 % $ 255 M usaUSA
Enochian Biosciences Enochian Biosciences
ENOB
116 M - - $ 40.5 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
724 M - - $ 1.01 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
3.53 B - - $ 867 M germanyGermany
Palatin Technologies Palatin Technologies
PTN
83.7 K $ 21.0 5.79 % $ 19.5 M usaUSA
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
78.6 M - -74.18 % $ 955 K usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
3.25 B - - $ 3.67 B usaUSA
Pulmatrix Pulmatrix
PULM
10.8 M $ 2.12 -1.4 % $ 7.74 M usaUSA
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
847 M $ 4.53 5.1 % $ 868 M canadaCanada
Homology Medicines Homology Medicines
FIXX
76.3 M - 0.77 % $ 53.4 M usaUSA